1. Introduction
Ulcerative colitis (UC) is a chronic inflammatory disease, within intestinal bowel diseases (IBD), characterized by a tissue destruction of large intestine with relapsing phases followed by periods of remission [
1]. The most common treatment strategies used include pharmacological therapy (steroidal and non-steroidal drugs) or, in the worst cases, removing portions of affected gastrointestinal tract through surgery. Although, pharmacological therapy has shown efficacies in ameliorating the severity and symptoms of IBD, typically does not lead to long periods of remission. Consequently, recent investigations have focused on the study of the impact of diet and healthy foods as potential alternative, and even the possible combination of nutraceuticals and healthy foods with pharmacological therapy in cases when the patient is not eligible for conventional therapy which could help extend remission periods and improve life quality of IBD patients [
2,
3,
4,
5,
6].
A recent meta-analysis has associated a high intake of fruit and vegetables with a reduction of UC in European population, suggesting that the intake of their bioactive compounds (fiber, antioxidant vitamins and phytochemicals such as polyphenols, carotenoids, isoflavones) could explain this inverse association [
7]. In murine colitis models, which mimic human pathology, it has been demonstrated the preventive effect on pro-inflammatory intestinal process associated to the intake of mango [
8] or pineapple [
9] juices, polyphenols-rich extracts from orange [
10] or its sub-products [
11], apple [
12] and pomegranate [
13]. Polyphenols seems to be the main bioactive compounds involved in the anti-colitic action of fruits, due to its ability to inhibit some pivotal pro-inflammatory mediators as nuclear transcriptional Factor-κB (NF-κB) and specific cytokines (Tumor Necrosis Factor-α (TNF-α), and interleukin 1-β (IL-1β)) and the induction of antioxidant defence systems. Furthermore, lipophilic compounds present in vegetables and fruits, such as fat-soluble vitamins (pro-vitamin A) [
14], carotenoids (β-carotene) [
15] and plant sterols (PS) [
16,
17,
18,
19,
20,
21], have displayed important anti-inflammatory and inmmunodulatory effects. In particular, PS could be a good strategy to prevent IBD, because they show a very little absorption in the intestine (0.5–2%) and reach the colon, where could exert anti-inflammatory effects. Moreover, the European Union authorized PS addition into milk-based fruit beverages [
22], among other foods, to achieve the necessary amount of 1.5–3 g PS/day (not attainable with normal diet) for the well-known cholesterol-lowering effect [
23]. PS have shown promising results in animal colitis models induced by trinitrobenzene sulfonic acid (TNBS) [
16,
17], dextran sodium sulphate (DSS) [
18,
19,
20,
21,
22,
23,
24] or high-fat diet (40–60%) [
19,
20,
21]. Doses between 20–150 mg/Kg/day help to mitigate some important parameters associated to UC such as symptoms, colon shortening and presence of edema, histopathology and myeloperoxidase (MPO) activity on colon tissue.
Other bioactive compounds that have gained attention are prebiotics, which stimulate selectively beneficial intestinal bacteria, helping to maintain intestinal mucosal barrier and enhance defense against pathogenic microorganism [
25]. In this sense, galactooligosacharides (GOS) have been proposed as an active ingredient to prevent or alleviate symptoms associated with IBD [
26]. Human clinical trials have demonstrated that consumption of GOS contained in chocolate or banana flavored chews (3.5–7 g/day) [
27] and sachets (5.5 g/day) [
28,
29], reduce different pro-inflammatory markers such as calprotectin in feces, plasma C-reactive protein [
28] and cytokines (IL-6, IL-1β and TNF-α) [
29], with a concomitant increase in levels of fecal secretory immunoglobulin A (sIgA) [
28] and reduction of common ulcerative colitis symptoms [
27]. However, in animal studies the effect of GOS on colitis is controversial. GOS (4 g/Kg/day) administration for 10 days increase bifidobacterial number in colon in a TNBS colitis induced murine model, but it was not linked with a reduction of pro-inflammatory markers as MPO activity and colon damage [
30]. On the other hand, in mice smad-3 feed with GOS (5 g/Kg/day) for 42 days an improvement of colitis severity and increase of natural killer activity were observed after colitis induction by
Helicobacter hepaticus [
31].
Enrichment of healthy foods with bioactive compounds could be an effective strategy to help mitigate the symptoms associated with IBD and extend remission periods [
3]. In this sense, milk-based fruit beverages could be a suitable nutritional matrix for this purpose due to its low-fat content and good sources of bioactive compounds such as polyphenols, carotenoids and vitamins. Moreover, previous studies of our research group have demonstrated the beneficial effect of PS enriched milk-based fruit beverages on oxidative stress prevention and intestinal epithelia integrity maintenance in Caco-2 cells [
32], as well as, their systemic anti-inflammatory properties, in hypercholesterolemic post-menopausal women, through the serum increase of anti-inflammatory cytokine IL-10 with concomitant reduction of IL-1β, cytokine which play an important role on the development of IBD [
33].
The present study investigates for the first time, the effect of the daily intake of a healthy food, as milk-based fruit beverages, enriched with bioactive compounds (PS and/or GOS) on clinical symptoms and inflammatory process of UC, using a pre-clinical chronic murine model induced by DSS. The aim of this preliminary study is to evaluate if PS enriched milk-based fruit beverages with/without GOS are a suitable dietetic strategy to help to mitigate the health problems associated with UC.
4. Discussion
To investigate the potential anti-inflammatory effects of PS enriched milk-based fruit beverages with or without GOS on UC, a model of chronic colitis induced by DSS in mice was selected. Although colitis animal models do not represent the complexity of human disease, they provide valuable information about factors involved in the inflammatory process and allow to evaluate different therapeutic strategies to improve life quality of patients with IBD [
38]. In particular, the DSS-induced colitis model can easily reproduce the acute and chronic phases or the relapsing periods typical of UC, depending on the concentration and cycles of exposition to DSS in drinking water. Moreover, this model exhibits similar symptoms to those of human UC (diarrhea, bloody feces and body weight loss) and histological features such as mononuclear leucocyte infiltration, crypt architectural disruption and epithelial degeneration [
39].
Our study showed that daily administration of MfB beverage resulted in a significant (
p < 0.05) reduction of symptoms associated to UC, mainly preventing the presence of diarrhea or alleviating their increase during all experiment (vs. DSS group), as well as, protecting against presence of bloody feces in the acute phase of the disease (first DSS cycle). Reduction of clinical symptoms led to partially prevention of colon shortening induced by DSS cycles, showing longer colons (18%) compared to DSS group. Histopathological analysis of the colon revealed a slight improvement in the architecture of the colonic epithelium and a greater number of crypts compared to the DSS group, in agreement with the previous parameters mentioned. However, the distribution and morphology of the crypts were altered, as well as an increase of neutrophil infiltration and a high MPO level in the colonic tissue was observed. Stimulation of neutrophil activity or its migration into colon tissue, could be related with the prevention of colon shortening observed after MfB treatment. Neutrophils are considered the first line of defence against microorganisms and recently, it has been demonstrated that they can build a complex formed by chromatin and neutrophil proteins that act as immunomodulator and activate immune cells such as T cells, although their specific role on IBD has not been well described yet [
40]. Beneficial effect of MfB upon DSS-induced colitis can also be related with its cytoprotective effect at intestinal level. In a previous in vitro study by our research group, it was demonstrated that milk-based fruit beverages had several beneficial effects against oxidative stress and prevention of cell dead, inhibiting some important pro-apoptotic events and preserving cell monolayer integrity in a differentiated colon cancer (Caco-2) cell model [
32]. This fact could be important because DSS is a toxic compound to colonic epithelial cells that cause an increase of apoptotic cells and compromise the epithelial barrier integrity through the loss of some important proteins present in the tight junctions [
41].
It is important to note our study design does not allow knowing which bioactive compound/s contained in the beverages has the anti-inflammatory effect on DSS-induced colitis. Nevertheless, it may be possible that the specific combination of all of them produce the effect observed in our study. The presence of mandarin juice (represents almost half of MfB composition), could contribute to the anti-inflammatory effect since contains important quantities of antioxidant phytochemicals such as flavonoids (mainly hesperidin, narirutin and vicenin-2) and β-cryptoxanthin (β-Cx) [
42]. In this sense, flavonoid-rich extracts (containing mainly hesperidin, narirutin and vicenin-2) obtained from blood orange juice administrated (40 mg/kg/day) to CD1 mice with colitis-induced by dinitrobenzene sulfonic acid, have shown preventive effects against the colonic pathological tissue damage. Flavonoids acted mainly counteracting NF-κB signalling, decreasing expression of pro-apoptotic proteins (Bax) and restoring the redox balance in colonic tissue [
10]. Similar effects were observed in a recent study with industrial orange by-products (citrus pectin and different sub-fractions obtained from orange after juice extraction) in DSS-treated mice [
11]. Byproducts with high polyphenol total content and antioxidant capacity showed better anti-inflammatory effect in terms of clinical symptoms and reduction of pro-inflammatory mediators’ expression (TNF-α, IL-1β, IL-6). On the other hand, the presence of β-Cx could contribute to the beneficial effects of the MfB, although its specific role on UC has not been studied yet. In steatohepatitis and insulin resistance murine models induced by high fat content diets, β-Cx administration (~2.5–7.5 mg/kg/day) lead to attenuation of lipotoxicity-induced inflammation, preventing hepatic tissue peroxidation (TBARS) and the macrophages activation [
43], as well as the stimulation of antioxidant enzymes (catalase, superoxide dismutase and glutathione peroxidase) and inhibition of the expression of pro-inflammatory markers (NF-κB and TNFα) in liver [
44]. Therefore, β-Cx is able to reduce the pro-inflammatory process through a direct and indirect anti-oxidant mechanism. Taking into account that oxidative stress has a pivotal role on UC, daily administration of MfB containing β-Cx (0.02 mg/kg/day) could help to mitigate the pro-inflammatory process.
Additionally, it is important to note that enrichment of MfB with PS could be a remarkable factor in its anti-colitic effect, since several studies using PS standard solutions (β-sitosterol, stigmasterol and γ-oryzanol) added to feed and administered at doses between 20–50 mg/kg/day (similar to our study 35 mg/kg/day) for 3-56 days have shown a marked anti-inflammatory effect independently of the colitis animal model used. In C57BL/6 mice, β-sitosterol (20 mg/kg/day) administration for 56 days prevented the colon shortening (~8%) and reduced MPO activity in colon tissue (~35%), what led to a lower level of pro-inflammatory cytokines (IL-1β, TNF-α and IL-6) after colitis induction by high fat diet (60 Kcal% from fat) [
16]. Similarly, β-sitosterol administration (10 or 20 mg/kg) during 3 days to C57BL/6 mice with colon inflammation induced by TNBS prevented partially colon shortening (~3.4%) and improved the pro-inflammatory status, reducing pro-inflammatory cytokine levels (IL-1β, TNF-α and IL-6) and MPO activity in colon tissue (~42%), with a concomitant inhibition of NF-κB translocation into the nucleus [
17]. In UC models induced by DSS, administration to C57BL/6 mice of γ-oryzanol (50 mg/Kg/day for 16 days), a mixture of phytosteryl ferulates derived from rice bran oil, mitigated clinical symptoms associated to UC and partially prevented colon shortening (~9%) and the pathophysiological activity during colonic inflammation through inhibition of NF-κB activation after 5 days of DSS at 3% (v/v) induction [
24]. Differences observed in terms of MPO activity with respect to our study, could be attributed to the fact that PS are added into the beverages as a food ingredient composed of a complex mixture of PS (β-sitosterol, sitostanol, campesterol, campestanol and stigmasterol). As far as we know, there are no studies that evaluate the anti-inflammatory effect—in murine chronic colitis models—of some of the PS found in the food ingredient used in the PS enrichment of our beverages (sitostanol, campesterol and campestanol), which suppose 20% of the total PS. The small molecular structural differences among sitostanol, campesterol or campestanol, in comparison to β-sitosterol, could explain the lack of beneficial effect observed on the pro-inflammatory process. Feng et al. [
21] observed that β-sitosterol or stigmasterol administration (0.4% w/w) in C57BL/6J mice similarly mitigate inflammation severity and macroscopic damage (colon shortening and histopathology score) induced by DSS (1.5%
w/
v, for 5 days), but only stigmasterol was able to reduce the expression of cyclooxygenase-2. Authors indicate that the presence of a double-bond in the side chain in stigmasterol could be responsible for their additional anti-inflammatory effect compared to β-sitosterol. In this sense, different behaviour of β-sitosterol, campesterol and stigmasterol at the same concentration (24 µM for 48 h) and cell system (macrophages) have been observed. Stigmasterol suppressed cytokine secretion into the supernatant, while β-sitosterol promoted it and campesterol did not have any effect [
45]. Moreover, it is also possible that some specific compounds present in our beverages hidden the beneficial effects of PS on colitis. Llewellyn et al. [
46] observed that administration of a high casein diet (41% w/w) for 14 days promoted intestinal barrier damage and increased colonic cytokines levels (IL-6 and TNF-α) in DSS induced model in mice (3%
w/
v for 7 days). Although, the casein intake is around 850-fold higher than our study, the longer administration time of beverage (14 vs. 56 days) and DSS (7 vs. 56 days) exposition could explain our results. Besides, the potential impact of other compounds present in the beverage on the colitis process cannot be ruled out.
Regarding the potential beneficial effect of GOS on DSS-induced colitis, results show that MfB-G administration during all the experiment does not confer additional beneficial effects with respect to MfB. DSS + MfB-G mice suffered a dramatic increase of clinical symptoms from the third DSS cycle, remaining constant up to the end of the study. This fact could explain the absence of a beneficial effect of MfB-G on colon shortening (12% shorter than MfB), the higher colonic mucosa alteration (distortion of crypts and high immune cells infiltration) and MPO level compared to MfB. The effect of GOS and mechanisms which could improve UC in murine colitis models have been poorly studied and currently are controversial. Holma et al. [
30] reported that administration to rats of two kinds of GOS (whey and lactose derived from cow milk) at 4 g/kg/day for 10 days increased notably bifidobacterial number in feces, which are high producers of anti-inflammatory compounds, such as short-chain fatty acids. However, the increase of bifidobacterial number was not correlated with an improvement of colonic damage and they did not prevent immune cell infiltration (MPO activity) and edema induced by TNBS during 72 h. In contrast, in mice deficient in
smad-3 (phenotype characterized by colon moderate inflammatory response) infected by
Helicobater hepaticus, GOS supplementation (5 g/kg/day) for 42 days reduced colitis severity preserving colon architecture by modulating the function and trafficking of natural killer cells [
31]. The use of different animal species, agents of induction of colitis, treatment times and type of GOS could explain the differences found between the studies. However, it has been reported previously the harmful effect of fructooligosacharides (FOS) administration (at 6 g/day), a kind of soluble fibre similar to GOS, in rats with colitis induced by DSS (at 3% for seven days). Similar to our results, FOS slightly prevented symptoms associated to UC (13–45%, DAI value) at the beginning of the study but quickly worsened without showing differences with respect to DSS group up to the end of the study. FOS treatment did not prevent the colon shortening and exacerbated colon histological damage severity and MPO activity, as well as reduced crypt cell proliferation in the distal colon, which is an integral part of the colon repair process. Authors indicated that FOS delayed the onset of repair, promoting the harmful effect of DSS on colon epithelia [
47]. Other possible hypothesis could be related with the bifidogenic effect of FOS, what lead to the increase of bifidobacterial genus in the colon. It has been indicated that a quick rate of FOS fermentation in the cecum produce an overproduction of organic acids as lactic and acetic acids [
48], which can damage the intestinal epithelium, leading to an increase of colonic permeability [
49]. Similar to FOS, it has been indicated that GOS fermentation (72 h) lead to a quick increase and accumulation of lactic and acetic acids in the colon, compared to propionic and butyric acids, in a dynamic in vitro colon model (TIM-2). These increases were correlated with an increase of bifidobacteria and lactobacilli genus [
50]. Then, we hypothesized that MfB-G administration could produce a change in intestinal microbiota by increasing the organic acids that produce bacteria, which could exacerbate the loss of the epithelial barrier integrity and the colonic mucosal permeability induced by DSS. Moreover, the potential inhibitory effect of GOS on the colonic repair mechanism cannot be ruled out.
In summary, PS-enriched milk-based fruit beverage (MfB) shows a moderate anti-inflammatory effect, helping to alleviate the clinical symptoms associated to colitis, the colon shortening and colonic damage in a DSS-induced mice model of chronic colitis. Neutrophil infiltration in colonic tissue and MPO level remained higher after MfB treatment, suggesting that they could be involved in its anti-inflammatory action as a compensatory mechanism trying to overcome the damage induced by DSS. GOS addition to the MfB did not show any additional beneficial effects in comparison with MfB and even exacerbated the pro-inflammatory action induced by DSS. The higher DAI value, colonic mucosa damage, immune cell infiltration and MPO level, suggest that presence of GOS in colon compromise colonic epithelial permeability or delay the reparation colonic mechanism, promoting the cytotoxic effect of DSS on colon cells.
Our results demonstrate the importance to evaluate the biological effects of bioactive compounds in the context of a complex food matrix. PS-enriched foods could be a suitable strategy to extend remission periods and improve the quality of life of patients with UC, but further investigation is needed to confirm the beneficial role of PS in a food matrix on the UC.